In a nutshell
This study aimed to evaluate the effectiveness of treatments for erectile dysfunction after prostate surgery. This study found similar effectiveness between phosphodiesterase type 5 inhibitors (PDE5l) taken as part of a schedule or as needed to treat ED.
Some background
Prostate surgery is a treatment option for prostate cancer. Erectile dysfunction (ED) can occur as a side-effect of this surgery. ED is the inability to get or keep an erection firm enough to have sexual intercourse. Medications can be used to treat erectile function. One common medication type is a phosphodiesterase type 5 inhibitor (PDE5l) such as sildenafil (Viagra) or tadalafil (Cialis). However, what is the best way to treat ED after prostate surgery is still unknown.
Methods & findings
This study reviewed eight other studies including 1699 patients. Patients were given either PDE5Is or a placebo. Patients took the medication either on a schedule (such as a daily prescription) or when needed. One study analyzed compared the use of a PDE5I with a drug placed into the tip of the penis like a suppository, called a prostaglandin E1 (PgE1).
In patients taking PDE5I medications, there were no significant differences in side-effects or effectiveness in those on a schedule or taking as needed. Compared to placebo, PDE5Is showed a slightly higher effectiveness in erectile function up to 12 months.
On the short-term (up to 12 months), PDE5ls led to a small improvement in erectile function when compared to the PgE1.
The bottom line
This study found that the main treatment for men with ED after prostate surgery were PDE5ls. The authors suggested that they had similar effectiveness when they were as part of a schedule or as needed.
The fine print
The studies analyzed were of a low quality. Further studies are needed for more firm recommendations.
What’s next?
If you have any concerns about treatment for ED, discuss with your doctor.
Published By :
Cochrane database of systematic reviews
Date :
Oct 23, 2018
